In summary, the current study is the first functional study exploring a FANCD2 malignant phenotype in ESCC development, through regulating cell cycle progression (Figure 6c), suggesting that FANCD2 may serve as a prognostic biomarker and potential drug target in ESCC management. Here, FANCD2 is linked to esophageal squamous cell carcinoma.